Ct-179

Phase 1

OOlivia Newton-John Cancer Research Institute

Ct-179 is one of 7 therapeutic programs targeting Recurrent Glioblastoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Recurrent GlioblastomaNot yet recruiting

Recurrent GlioblastomaPhase 1

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Recurrent Glioblastoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

2 2

Avastin

Roche

Phase 2

2 3

Tecentriq

Roche

Phase 2

2 4

Cabometyx

Bristol-Myers Squibb

Preclinical

1 5

ACT001

NNationwide Children's Hospital

Phase 2

1 6

Ct-179

OOlivia Newton-John Cancer Research Institute

Phase 1

1 7

LMP744

NNational Cancer Institute (NCI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Not yet recruiting

Recurrent Glioblastoma

NCT07739017

Clinical

Trials by Indication[1]

Recurrent Glioblastoma1 trial

A Phase 1, Two-Part, Accelerated Dose Titration Trial of CT-179 as Monotherapy in the Treatment of Recurrent Glioblastoma and in Combination With Radiation Therapy in the Treatment of Newly Diagnosed MGMT-Unmethylated Glioblastoma

Not yet recruiting·OOlivia Newton-John Cancer Research Institute·Phase 1·NCT07739017·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ct-179. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ct-179. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Olivia Newton-John Cancer Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: OOlivia Newton-John Cancer Research Institute

Ct-179

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Recurrent Glioblastoma1 trial

References

Drug Info

Quick Facts

Related News